Effects of Stigmasterol and β-Sitosterol on Nonalcoholic Fatty Liver Disease in a Mouse Model: A Lipidomic Analysis

J Agric Food Chem. 2018 Apr 4;66(13):3417-3425. doi: 10.1021/acs.jafc.7b06146. Epub 2018 Mar 27.

Abstract

To study the effects of stigmasterol and β-sitosterol on high-fat Western diet (HFWD)-induced nonalcoholic fatty liver disease (NAFLD), lipidomic analyses were conducted in liver samples collected after 33 weeks of the treatment. Principal component analysis showed these phytosterols were effective in protecting against HFWD-induced NAFLD. Orthogonal projections to latent structures-discriminate analysis (OPLS-DA) and S-plots showed that triacylglycerols (TGs), phosphatidylcholines, cholesteryl esters, diacylglycerols, and free fatty acids (FFAs) were the major lipid species contributing to these discriminations. The alleviation of NAFLD is mainly associated with decreases in hepatic cholesterol, TGs with polyunsaturated fatty acids, and alterations of free hepatic FFA. In conclusion, phytosterols, at a dose comparable to that suggested for humans by the FDA for the reduction of plasma cholesterol levels, are shown to protect against NAFLD in this long-term (33-week) study.

Keywords: cholesterol; fatty liver; lipidomics; mice; stigmasterol; β-sitosterol.

MeSH terms

  • Animals
  • Cholesterol / metabolism
  • Diet, High-Fat / adverse effects
  • Disease Models, Animal
  • Humans
  • Lipid Metabolism / drug effects*
  • Liver / drug effects
  • Liver / metabolism
  • Male
  • Mice
  • Mice, Inbred C57BL
  • Non-alcoholic Fatty Liver Disease / drug therapy*
  • Non-alcoholic Fatty Liver Disease / metabolism
  • Sitosterols / administration & dosage*
  • Stigmasterol / administration & dosage*
  • Triglycerides / metabolism

Substances

  • Sitosterols
  • Triglycerides
  • gamma-sitosterol
  • Cholesterol
  • Stigmasterol